The discovery of driver mutations and chromosomal rearrangements in NSCLC has resulted in the availability of molecularly targeted agents for 40% of NSCLC (30), including EGFR tyrosine kinase inhibitors (TKIs) and ALK TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.